跳转至内容
Merck

1598405

USP

雷尼替丁 盐酸盐

United States Pharmacopeia (USP) Reference Standard

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C13H22N4O3S · HCl
CAS号:
分子量:
350.86
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

ranitidine

製造商/商標名

USP

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

Cl[H].CN\C(NCCSCc1ccc(CN(C)C)o1)=C\[N+]([O-])=O

InChI

1S/C13H22N4O3S.ClH/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3;/h4-5,9,14-15H,6-8,10H2,1-3H3;1H/b13-9-;

InChI 密鑰

GGWBHVILAJZWKJ-CHHCPSLASA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Ranitidine hydrochloride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
  • Ranitidine Injection
  • Ranitidine Tablets
  • Ranitidine in Sodium Chloride Injection
  • Ranitidine Oral Solution

生化/生理作用

H2 组胺受体拮抗剂;抗溃疡剂。

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

相關產品

产品编号
说明
价格

象形圖

Health hazardExclamation mark

訊號詞

Danger

危險分類

Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Travis Nemkov et al.
JCI insight, 6(3) (2020-12-23)
Computational models based on recent maps of the RBC proteome suggest that mature erythrocytes may harbor targets for common drugs. This prediction is relevant to RBC storage in the blood bank, in which the impact of small molecule drugs or
Question 1: does the use of ranitidine increase the risk of NEC in preterm infants?
Manigandan Chandrasekaran et al.
Archives of disease in childhood, 99(4), 390-392 (2014-03-15)
Natalia Alonso et al.
The Biochemical journal, 459(1), 117-126 (2014-01-15)
7TMRs (seven-transmembrane receptors) exist as conformational collections in which different conformations would lead to differential downstream behaviours such as receptor phosphorylation, G-protein activation and receptor internalization. In this context, a ligand may cause differential activation of some, but not all
[The development of hemorrhagic vasculitis (Schönlein-Henoch disease) in a patient with a chronic stomach ulcer against a background of Sostril (ranitidine hydrochloride) therapy].
E N Glazunov et al.
Vestnik khirurgii imeni I. I. Grekova, 152(1-2), 102-103 (1994-01-01)
T S Gaginella et al.
Drug intelligence & clinical pharmacy, 17(12), 873-885 (1983-12-01)
Ranitidine is a selective, competitive histamine H2-receptor antagonist recently approved by the Food and Drug Administration for use in the short-term treatment of active duodenal ulcers and gastric hypersecretory conditions. Ranitidine is four to ten times more potent than cimetidine

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门